<< M. D. Anderson Cancer Center recommends colonoscopy screening to reduce risk of colon cancer | Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | हिन्दी | Norsk | Русский | Svenska | Polski

FDA warns healthcare professionals about bogus surgical mesh products

Published on March 11, 2010 at 11:46 PM · No Comments

The U.S. Food and Drug Administration today warned health care providers and consumers about counterfeit surgical mesh being distributed in the United States under the C. R. Bard/Davol brand name. Surgical mesh products are used to reinforce soft tissue where weakness exists.

The warning is of particular significance to health care professionals and their patients with surgical mesh implants as well as hospitals and surgical centers, operating room medical professionals and staff, and purchasing and risk managers.

Investigations by the FDA and Bard show that the following products, sizes and lots of counterfeit flat sheet polypropylene surgical mesh are not manufactured by Bard. To date, four product sizes have been identified:

The FDA is recommending that health care professionals:

Do not use any counterfeit Bard surgical mesh from the lots listed

Carefully examine all manufacturers' polypropylene surgical mesh products and packaging for lot numbers and anything unusual that might indicate counterfeit mesh

Contact Bard at 800-556-6275 if they think they have one of the counterfeit products

Contact the particular manufacturer if they notice anything unusual or suspicious with any other brand of surgical mesh product or packaging.

The FDA also recommends that health care professionals continue to monitor patients for adverse events as they would any patient with an authentic polypropylene surgical mesh implant, if they suspect or know that counterfeit mesh has been implanted.

Patients should contact their surgeon if they experience problems that they think may be related to surgical mesh.

The FDA continues to gather information and data on the counterfeit mesh to better understand its potential public health impact. The agency also is working to determine who may be responsible and how the counterfeiting and distribution occurred.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading